Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 670-676

  Hakansson A ^a   Gustafsson, B ^a   Krysander, L ^a   Hakansson L ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fine needle aspiration; Interferon alpha; Malignant melanoma; Tumour infiltrating mononuclear cell

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; CYCLOPHOSPHAMIDE; GLYCOPROTEIN P 15095; INDOMETACIN; OKT 4; OKT 8;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; METHODOLOGY; MONONUCLEAR CELL; NEEDLE BIOPSY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC DISEASE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR REGRESSION;

EID: 0029738930     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.420     Document Type: Article

References (28)

1. ABERSHOLD P, HYATT C, JOHNSON S, HINES K, KORCAK L, SANDERS M, LOTZ M, TOPALIAN S, YANG J AND ROSENBERG SA. (1991). Lysis of autologous melanoma cells by tumour infiltrating lymphocytes: association with clinical response. J. Natl Cancer Inst., 83, 932-937.
2. BALCH CM, MURAD TM, SOONG S-J, INGALS AL, HALPERN NB AND MADDOX WA. (1978). A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann. Surg. 188, 732-742.
3. BALKWILL F. (1989). Interferons. Lancet, 1(8646), 1060-1063.
4. CREAGAN ET, SCHAID DJ, AHMANN DL AND FRYTAK S. (1988). Recombinant interferons in the management of advanced malignant melanoma. Am. J. Clin. Oncol., 11, 652-659.
5. GRESSER I. (1990). Biologic effects of interferons. J. Invest. Dermatol., 95, (suppl.), 66S-71S.
6. HANSEN MG AND MCCARTEN AB. (1974). Tumour thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am. J. Surg., 128, 557-561.
7. HURWITZ PJ. (1991). Spontaneous regression of metastatic melanoma. Ann. Plast. Surg., 26, 403-406.
8. HUTCHINSON GH, HEINEMANN D, SYMES MO AND WILLIAMSON RCN. (1981). Differential immune reactivity of tumour intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells. Br. J. Cancer, 44, 396-402.
9. JONES PC, SZE LL, LIU PY, MORTON DL AND IRIE RF. (1981). Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Nail Cancer Inst., 66, 249-254.
10. KANG S, BARNHILL RL, MIHM MC AND SOBER AJ. (1993). Histologic regression in malignant melanoma: an interobserver concordance study. J. Cutan. Pathol., 126-129.
11. KIRKWOOD JM, HUNT STRAWDERMAN M, ERNSTOFF MS, SMITH TJ, BORDEN EC AND BLUM RH. (1996). Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1648. J. Clin. Oncol., 14, 7-17.
12. KNOP J. (1990). Immunologic effects of interferon. J. Invest. Dermatol., 95, (suppl.), 72S-74S.
13. KORNSTEIN MJ, BROOKS JSJ AND ELDER DE. (1983). Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res., 43, 2749-2753.
14. LARSEN TE AND CRUDE TH. (1978). A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. Acta Pathol. Microbiol. Scand., 86, 523-530.
15. LEGHA SS. (1989). Current therapy for malignant melanoma. Semin. Oncol., 16, 34-44.
16. MCGOVERN VJ. (1975). Spontaneous regression of melanoma. Pathology, 7, 91-99.
17. MCGOVERN VJ, SHAW HM, MILTON GW AND FARAGO GA, (1981). Lymphocytic Infiltration and Survival in Malignant Melanoma. In Pathology of Malignant Melanoma, Ackerman AB (ed.) pp. 341-344. Masson Publishing.
18. MIESCHFR S, WHITFSIDE TL, CARREL S AND VON FLIEDNER V. (1986). Functional properties of tumour-infiltrating and blood lymphocytes in patients with solid tumours: effects of tumour cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136, 1899 1907.
19. MIESCHER S, STOECK M, QIAO L, BARRAS C, BARRELET L AND VON FLIEDNER V. (1988). Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumours. Cancer Res., 48, 6992 6998.
20. POPPHMA S, BRÖCKER EB, DE LEIJ L, TERBRACK D, VISSCHER T, TER HAAR A, MACHER E, THE TH AND SORG C. (1983). In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin. Exp. Immunol., 51, 77 82.
21. RONAN SG, ENG AM, BRIELE HA, SHIOURA NN AND DAS GUPTA TK. (1987). Thin malignant melanomas with regression and metastases. Arch. Dermatol., 123, 1326 1330.
22. ROSENBERG SA, SPIESS P AND LAFRENIERE R. (1986). A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science, 233, 1318 1321.
23. ROSENBERG SA, PACKARD BS, AEBERSHOLD PM, SOLOMON D, TOPALIAN SL, TOY ST, SIMON P, LOTZE MT, YANG JC, SEIPP CA, SIMPSON C, CARTER C, BOCK S, SCHWARTZENTRUBER D, WEI JP AND WHITH DE. (1988). Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319, 1676-1680.
24. RUITER DJ, BHAN AK, HARRIST TJ, SOBER AJ AND MIHM MC. (1982). Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol., 129, 2808-2815.
25. SONDERGAARD K AND HOU-JENSEN K. (1985). Partial regression in thin primary cutaneous malignant melanomas clinical stage I. Virchows Arch. A Pathol. Anat. Histopathol., 408, 241 247.
26. TEFANY FJ, BARNETSON R STC, HALLIDAY GM, MCCARTHY SW AND MCCARTHY WH. (1991). Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J. Invest. Dermatol., 97, 197-202.
27. VOSE BM AND MOORE M. (1985). Human tumour-infiltrating lymphocytes: a marker of host response. Semin. Hematol., 22, 27 40.
28. WHITESIDE TL, EORENZ MJ AND HERBERMAN RB. (1992). Tumour-infiltrating lymphocytes: potential and limitations to their use for cancer therapy. Crit. Rev. Oncol. Hematol., 12, 25 47.